Uterine Carcinosarcoma Clinical Trial
Official title:
A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to find out whether biomarkers in the blood can predict the cancer's response to the study treatment. A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01168232 -
Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00390234 -
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00245102 -
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
|
Phase 2 | |
Completed |
NCT00025506 -
Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus
|
Phase 2 | |
Recruiting |
NCT05902988 -
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05619913 -
EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00687687 -
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
|
Phase 2 | |
Completed |
NCT00114218 -
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Terminated |
NCT01367301 -
Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer
|
N/A | |
Withdrawn |
NCT03902379 -
Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer
|
N/A | |
Completed |
NCT03694262 -
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
|
Phase 2 | |
Completed |
NCT01247571 -
Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Terminated |
NCT01061606 -
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
|
Phase 2 | |
Completed |
NCT00075400 -
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
|
Phase 2 | |
Completed |
NCT00659360 -
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
|
Phase 2 | |
Completed |
NCT00238121 -
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00954174 -
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
|
Phase 3 | |
Completed |
NCT00478426 -
Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT05229601 -
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
|
Phase 1 |